American Journal of Health-System Pharmacy, Vol. 62, Issue 2,
173-181
Copyright © 2005 by American Society of Health-System Pharmacists
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus
Orville G. Kolterman,
Dennis D. Kim,
Larry Shen,
James A. Ruggles,
Loretta L. Nielsen,
Mark S. Fineman and
Alain D. Baron
ORVILLE G. KOLTERMAN, M.D., is Senior Vice-President, Clinical Affairs; DENNIS D. KIM, M.D., is Senior Director, Medical Affairs; LARRY SHEN, PH.D., is Senior Director, Biometrics; JAMES A. RUGGLES, PH.D., is Associate Director Medical Writing, Medical Affairs; LORETTA L. NIELSEN, PH.D., is Senior Medical Writer, Medical Affairs; MARK S. FINEMAN, B.S., is Senior Director, Clinical Affairs; and ALAIN D. BARON, M.D., is Senior Vice-President Research, Amylin Pharmaceuticals Inc., San Diego, CA.
Address correspondence to Dr. Kolterman at Amylin Pharmaceuticals Inc., 9360 Towne Centre Drive, Suite 110, San Diego, CA 92121 (okolterman{at}amylin.com).
|
Purpose. The pharmacology and tolerability of exenatide in patients with type 2 diabetes mellitus were studied.
Methods. Two randomized, single-blind, placebo-controlled studies were conducted. Treatment with oral antidiabetic agents was stopped 14 days before study initiation. In the first study (study A), eight subjects received placebo, 0.1-, 0.2-, 0.3-, and either 0.4-µg/kg exenatide or placebo five minutes before a meal combined with liquid acetaminophen (to assess the rate of gastric emptying) on days 1, 3, 5, 7, and 9. In the second study (study B), subjects received a single s.c. dose of exenatide or placebo on consecutive days. Part 1 of study B used exenatide doses of 0.01 and 0.1 µg/ kg; 0.02-, 0.05-, and 0.1-µg/kg doses were given in part 2. After an overnight fast, the study drug was injected 15 minutes before a meal (part 1) and before a meal and acetaminophen (part 2). Parts 1 and 2 of study B enrolled six and eight patients, respectively.
Results. In both studies, plasma exenatide pharmacokinetic profiles appeared dose proportional. Exenatide doses of 0.020.2 µg/kg dose-dependently lowered postprandial glucose excursions. Exenatide suppressed postprandial plasma glucagon and slowed gastric emptying. There were no serious adverse events and no patient withdrawals related to treatment. Nausea and vomiting were the most common adverse events and were mild to moderate in severity at doses ranging from 0.02 to 0.2 µg/kg.
Conclusion. Administration of preprandial exenatide by s.c. injection resulted in dose-proportional exenatide pharmacokinetics and antidiabetic pharmacodynamic activity. At doses ranging from 0.02 to 0.2 µg/kg, exenatide dose-dependently reduced postprandial plasma glucose excursion by insulinotropism, suppression of plasma glucagon, and slowing of gastric emptying.
Index terms: Antidiabetic agents; Blood levels; Diabetes mellitus; Dosage; Drug administration routes; Exenatide; Gastric emptying; Mechanism of action; Pharmacodynamics; Pharmacokinetics; Toxicity
|
This article has been cited by other articles:

|
 |

|
 |
 
L. T. Meade
Practical Use of Exenatide and Pramlintide for the Treatment of Type 2 Diabetes
Journal of Pharmacy Practice,
December 1, 2009;
22(6):
540 - 545.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. FREEMAN
Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus
Cleveland Clinic Journal of Medicine,
December 1, 2009;
76(Suppl_5):
S12 - S19.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. K. Campbell and S. Miller
New Therapeutic Horizons: Mapping the Future of Glycemic Control With Incretin-based Therapy
The Diabetes Educator,
September 1, 2009;
35(5):
731 - 747.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Timmers, J. P.S. Henriques, D. P.V. de Kleijn, J. H. DeVries, H. Kemperman, P. Steendijk, C. W.J. Verlaan, M. Kerver, J. J. Piek, P. A. Doevendans, et al.
Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.
J. Am. Coll. Cardiol.,
February 10, 2009;
53(6):
501 - 510.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Matthews, M. W. Stewart, E. H. De Boever, R. L. Dobbins, R. J. Hodge, S. E. Walker, M. C. Holland, M. A. Bush, and for the Albiglutide Study Group
Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab.,
December 1, 2008;
93(12):
4810 - 4817.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Kim and J. M. Egan
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
Pharmacol. Rev.,
December 1, 2008;
60(4):
470 - 512.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A. Kothare, H. Linnebjerg, Y. Isaka, K. Uenaka, A. Yamamura, K. P. Yeo, A. de la Pena, C. H. Teng, K. Mace, M. Fineman, et al.
Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Mellitus
J. Clin. Pharmacol.,
December 1, 2008;
48(12):
1389 - 1399.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. J. Holst
Pharmacology of GLP-1-based therapies
The British Journal of Diabetes & Vascular Disease,
November 1, 2008;
8(2_suppl):
S10 - S18.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Gallwitz
Managing the {beta}-cell with GLP-1 in type 2 diabetes
The British Journal of Diabetes & Vascular Disease,
November 1, 2008;
8(2_suppl):
S19 - S25.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
C. W. Chia and J. M. Egan
Incretin-Based Therapies in Type 2 Diabetes Mellitus
J. Clin. Endocrinol. Metab.,
October 1, 2008;
93(10):
3703 - 3716.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Ionut, D. Zheng, D. Stefanovski, and R. N. Bergman
Exenatide can reduce glucose independent of islet hormones or gastric emptying
Am J Physiol Endocrinol Metab,
August 1, 2008;
295(2):
E269 - E277.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. F Van Gaal, S. W Gutkin, and M. A Nauck
Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?
Eur. J. Endocrinol.,
June 1, 2008;
158(6):
773 - 784.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Salehi, B. A. Aulinger, and D. A. D'Alessio
Targeting {beta}-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins
Endocr. Rev.,
May 1, 2008;
29(3):
367 - 379.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. L. Martin
Beyond Glycemic Control: The Effects of Incretin Hormones in Type 2 Diabetes
The Diabetes Educator,
May 1, 2008;
34(Supplement_3):
66S - 72S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. D. Bloom and M. F. Crutchlow
New-Onset Diabetes Mellitus in the Kidney Recipient: Diagnosis and Management Strategies
Clin. J. Am. Soc. Nephrol.,
March 1, 2008;
3(Supplement_2):
S38 - S48.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. J. Holst
The Physiology of Glucagon-like Peptide 1
Physiol Rev,
October 1, 2007;
87(4):
1409 - 1439.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Zinman, B. J. Hoogwerf, S. Duran Garcia, D. R. Milton, J. M. Giaconia, D. D. Kim, M. E. Trautmann, and R. G. Brodows
The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes: A Randomized Trial
Ann Intern Med,
April 3, 2007;
146(7):
477 - 485.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Soon, P. A. Kothare, H. Linnebjerg, S. Park, E. Yuen, K. F. Mace, and S. D. Wise
Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy asian men.
J. Clin. Pharmacol.,
October 1, 2006;
46(10):
1179 - 1187.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. K. Yoo, D. M. Triller, and D. J. Yoo
Exenatide: A New Option for the Treatment of Type 2 Diabetes
Ann. Pharmacother.,
October 1, 2006;
40(10):
1777 - 1784.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. S. Odegard, S. M. Setter, and J. L. Iltz
Update in the pharmacologic treatment of diabetes mellitus: focus on pramlintide and exenatide.
The Diabetes Educator,
September 1, 2006;
32(5):
693 - 712.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Fehse, M. Trautmann, J. J. Holst, A. E. Halseth, N. Nanayakkara, L. L. Nielsen, M. S. Fineman, D. D. Kim, and M. A. Nauck
Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes
J. Clin. Endocrinol. Metab.,
November 1, 2005;
90(11):
5991 - 5997.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. A. Gault, N. Irwin, B. D. Green, J. T. McCluskey, B. Greer, C. J. Bailey, P. Harriott, F. P.M. O'Harte, and P. R. Flatt
Chemical Ablation of Gastric Inhibitory Polypeptide Receptor Action by Daily (Pro3)GIP Administration Improves Glucose Tolerance and Ameliorates Insulin Resistance and Abnormalities of Islet Structure in Obesity-Related Diabetes
Diabetes,
August 1, 2005;
54(8):
2436 - 2446.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. R. Gedulin, S. E. Nikoulina, P. A. Smith, G. Gedulin, L. L. Nielsen, A. D. Baron, D. G. Parkes, and A. A. Young
Exenatide (Exendin-4) Improves Insulin Sensitivity and {beta}-Cell Mass in Insulin-Resistant Obese fa/fa Zucker Rats Independent of Glycemia and Body Weight
Endocrinology,
April 1, 2005;
146(4):
2069 - 2076.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 by the American Society of Health-System Pharmacists.
|
|